Showing results (81-90 of 196) with videos related to
Sort By:
Pageof 20
Clinical Journal of Gastroenterology|August 30, 2019
Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapyKazuki Ohya, Michio Imamura, Mitsutaka Osawa, et al.Oncology|November 11, 2024
First-Line Durvalumab plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma in Real-World Clinical PracticeYasutoshi Fujii, Tomokazu Kawaoka, Yuki Shirane, et al.Medicine|September 17, 2024
Real-world efficacy and safety of durvalumab-tremelimumab as second-line systemic therapy after atezolizumab-bevacizumab in unresectable hepatocellular carcinomaRyoichi Miura, Atsushi Ono, Shigeki Yano, et al.JCO Clinical Cancer Informatics|December 18, 2024
Prediction of Hepatocellular Carcinoma After Hepatitis C Virus Sustained Virologic Response Using a Random Survival Forest ModelHikaru Nakahara, Atsushi Ono, C Nelson Hayes, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|December 20, 2011
Hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic interferon-α for advanced hepatocellular carcinoma in combination with or without three-dimensional conformal radiotherapy to venous tumor thrombosis in hepatic vein or inferior vena cavaEisuke Murakami, Hiroshi Aikata, Daisuke Miyaki, et al.Bioorganic & Medicinal Chemistry Letters|June 29, 2010
Synthesis and anti-HCV activity of 3',4'-oxetane nucleosidesWonsuk Chang, Jinfa Du, Suguna Rachakonda, et al.Clinical Journal of Gastroenterology|February 2, 2019
Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shuntMaiko Namba, Tomokazu Kawaoka, Hiroshi Aikata, et al.Journal of Experimental & Clinical Cancer Research : CR|June 27, 2021
Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinibYasutoshi Fujii, Atsushi Ono, C Nelson Hayes, et al.Journal of Medical Virology|October 5, 2019
Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapyYuhei Saito, Michio Imamura, Takuro Uchida, et al.Clinical Journal of Gastroenterology|November 30, 2019
Isolated cardiac metastases of hepatocellular carcinoma after resection: a case reportYosuke Tamura, Tomokazu Kawaoka, Hiroshi Aikata, et al.Pageof 20